- Previous close
0.1410 - Open
0.1400 - Bid 0.1280 x 1000000
- Ask 0.1300 x 1621600
- Day's range
0.1280 - 0.1400 - 52-week range
0.0710 - 0.1850 - Volume
382,926 - Avg. Volume
495,583 - Market cap (intra-day)
113.668M - Beta (5Y monthly) 1.00
- PE ratio (TTM)
-- - EPS (TTM)
-0.0400 - Earnings date 26 Nov 2024
- Forward dividend & yield --
- Ex-dividend date --
- 1y target est
0.16
Pacific Edge Limited, a cancer diagnostics company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, and internationally. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the detection and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up for patients with haematuria who have a low probability of bladder cancer; Cxbladder Detect, which enables the risk stratification of patients with haematuria; and Cxbladder Monitor, a non-invasive surveillance alternative that reduces the burden of repeated cystoscopy in patients with a low risk of recurrence. In addition, the company is developing products for bladder, gastric, colorectal, endometrial cancers, and melanoma. Pacific Edge Limited was incorporated in 2001 and is headquartered in Dunedin, New Zealand.
www.pacificedgedx.com--
Full-time employees
31 March
Fiscal year ends
Healthcare
Sector
Diagnostics & Research
Industry
Recent news: PEB.NZ
View more
Performance overview: PEB.NZ
Trailing total returns as of 26/11/2024, which may include dividends or other distributions. Benchmark is .
YTD return
1-year return
3-year return
5-year return
Compare to: PEB.NZ
Select to analyse similar companies using key performance metrics; select up to four stocks.
Statistics: PEB.NZ
View moreValuation measures
Market cap
105.55M
Enterprise value
55.20M
Trailing P/E
--
Forward P/E
--
PEG ratio (5-yr expected)
--
Price/sales (ttm)
4.04
Price/book (mrq)
1.77
Enterprise value/revenue
2.12
Enterprise value/EBITDA
--
Financial highlights
Profitability and income statement
Profit margin
-117.07%
Return on assets (ttm)
-26.86%
Return on equity (ttm)
-43.00%
Revenue (ttm)
25.23M
Net income avi to common (ttm)
-29.54M
Diluted EPS (ttm)
-0.0400
Balance sheet and cash flow
Total cash (mrq)
50.26M
Total debt/equity (mrq)
7.46%
Levered free cash flow (ttm)
-18.1M